Selective inhibition of ErbB2-overexpressing breast cancer in vivo by a novel TAT-based ErbB2-targeting signal transducers and activators of transcription 3-blocking peptide

ErbB2 is an excellent target for cancer therapies. Unfortunately, the outcome of current therapies for ErbB2-positive breast cancers remains unsatisfying due to resistance and side effects. New therapies for ErbB2-overexpressing breast cancers continue to be in great need. Peptide therapy using cell...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer research (Chicago, Ill.) Ill.), 2006-04, Vol.66 (7), p.3764-3772
Hauptverfasser:	MING TAN, LAN, Keng-Hsueh, JUN YAO, LU, Chien-Hsing, MENGHONG SUN, NEAL, Christopher L, JING LU, DIHUA YU
Format:	Artikel
Sprache:	eng
Schlagworte:	Amino Acid Sequence Animals Antibodies, Monoclonal - pharmacokinetics Antibodies, Monoclonal - pharmacology Antineoplastic agents Biological and medical sciences Breast Neoplasms - drug therapy Breast Neoplasms - metabolism Drug Delivery Systems Female Gene Products, tat - pharmacokinetics Gene Products, tat - pharmacology Gynecology. Andrology. Obstetrics Human immunodeficiency virus Humans Immunoconjugates - pharmacokinetics Immunoconjugates - pharmacology Mammary gland diseases Medical sciences Mice Mice, SCID Molecular Sequence Data NIH 3T3 Cells Peptide Fragments - pharmacokinetics Peptide Fragments - pharmacology Pharmacology. Drug treatments Receptor, ErbB-2 - biosynthesis Receptor, ErbB-2 - metabolism STAT3 Transcription Factor - antagonists & inhibitors Tumors Xenograft Model Antitumor Assays
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!